InsiderTrades

Form 4 for FDMT 4D Molecular Therapeutics, Inc.

Accepted 2026-07-02 16:07:28 ET · period of report 2026-06-30 · accession 0001920738-26-000004 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DMT 2026-07-02 16:07 2026-06-30 FDMT Bizily Scott CLO M - OptEx $6.20 +6,566 15.2K +76% +$40.7K
DT 2026-07-02 16:07 2026-06-30 FDMT Bizily Scott CLO S - Sale+OE $14.00 -6,566 8,617 -43% -$91.9K
DMT 2026-07-02 16:07 2026-06-30 FDMT Bizily Scott CLO M - OptEx $0.00 -6,566 3,543 -65% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-06-30 M A 814 $4.14 9,431 D — —
2 Common Common Stock 2026-06-30 M A 5,752 $6.49 15,183 D — —
3 Common Common Stock 2026-06-30 S D 6,566 $14.00 8,617 D — — (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026.
4 Derivative Stock Option (Right to Buy) 2026-06-30 M D 814 $0.00 62,971 D $4.14 · — to 2035-03-05 814 Common Stock (F2) The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
5 Derivative Stock Option (Right to Buy) 2026-06-30 M D 5,752 $0.00 3,543 D $6.49 · — to 2032-06-17 5,752 Common Stock (F3) The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.